NDA 020785 · Bristol-Myers
Thalomid
Thalidomide · Oral
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Jul 16, 1998
Approved uses
2
Original approval plus efficacy supplements
Registered trials
431
94 Phase 3, 25 recruiting
FAERS reports
36,691
32,479 serious, 12,186 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM See full prescribing information for complete boxed warning. EMBRYO-FETAL TOXICITY • If THALOMID is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. THALOMID should never be used by females who are pregnant or who could be pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects. • Pregnancy must be excluded before start of treatment. Prevent pregnancy thereafter by the use of two reliable methods of contraception. ( 5.1 , 8.3 ) THALOMID is only available through a restricted distribution program, the Thalidomide REMS program ( 5.2 ). VENOUS THROMBOEMBOLISM • Significant increased risk of deep vein thrombosis (DVT) and pulmonary...
What it is approved for
From the label in effect Sep 3, 2026.
• THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 ) 1.1 Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM) [see Clinical Studies (14.1) ] . 1.2 Erythema Nodosum Leprosum THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence [see Clinical Studies (14.2) ].
Mechanism: The mechanism of action of THALOMID is not fully understood. Cellular activities of thalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. THALOMID possesses immunomodulatory, anti-inflammatory and antiangiogenic properties. Available data from in vitro studies and clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-α) production and down-modulation of selected cell surface adhesion...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 3, 2012 Supplement 40 · Efficacy LabelLetter
- Jul 16, 1998 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDALabelReview
4 products under this application
- THALOMID · THALIDOMIDE 50MG · CAPSULE, ORAL · Prescription · TE AB
- THALOMID · THALIDOMIDE 150MG · CAPSULE, ORAL · Prescription · TE AB
- THALOMID · THALIDOMIDE 100MG · CAPSULE, ORAL · Prescription · TE AB
- THALOMID · THALIDOMIDE 200MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Thalidomide" as an intervention, any sponsor and status, largest first.
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsPivotal-lookingStatus unknown
University of LeedsAcademic, hospital or other
NCT01554852 · 4,420 participants · Start May 2010 · Primary completion Dec 2021
Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen; Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen and 7 more · For: Multiple Myeloma
Sites: United Kingdom, United Kingdom
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT00689936 · 1,623 participants · Start Aug 21, 2008 · Primary completion Jul 14, 2016
Drug: Lenalidomide and low-dose dexamethasone; Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles and 1 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 288 sites in all
- A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple MyelomaPivotal-lookingCompleted
Intergroupe Francophone du MyelomeResearch network
NCT02541383 · 1,085 participants · Start Sep 2015 · Primary completion Aug 27, 2020
Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD); Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab and 1 more · For: Multiple Myeloma
Sites: Antwerp, Belgium; Bruges, Belgium; Brussels, Belgium · 107 sites in all
- Irinotecan Plus Thalidomide in Second Line Advanced Gastric CancerPivotal-lookingStatus unknown
Wang JufengAcademic, hospital or other
NCT02401971 · 900 participants (planned) · Start Aug 2014 · Primary completion Aug 2016
Drug: Thalidomide; CPT-11 · For: Gastric Cancer
Sites: Zhengzhou, China
- The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing ChemotherapyPivotal-lookingStatus unknown
Yunpeng LiuAcademic, hospital or other
NCT03601871 · 880 participants (planned) · Start Jul 12, 2018 · Primary completion Jun 30, 2020
Drug: Thalidomide; Dexamethasone and 1 more · For: Chemotherapy-induced Nausea and Vomiting
Sites: Haerbin, China; Siping, China; Anshan, China · 29 sites in all
- IFM 99-02 Thalidomide in MyelomaPivotal-lookingCompleted
University Hospital, ToulouseAcademic, hospital or other
NCT00222053 · 800 participants · Start Apr 2000 · Primary completion Sep 2009
Drug: Thalidomide; Biphosphonates · For: Multiple Myeloma
Sites: Toulouse, France · 5 sites in all
- Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung CancerPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00061919 · 724 participants · Start Apr 2003 · Primary completion Feb 2007
Drug: Carboplatin, etoposide & thalidomide; Carboplatin, etoposide & placebo · For: Lung Cancer
Sites: London, United Kingdom
- Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00075829 · 710 participants · Start Dec 2003 · Primary completion Jun 2012
Drug: Thalidomide; Dexamethasone · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 36 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death6,421
- disease progression2,495
- plasma cell myeloma2,058
- off label use1,842
- neuropathy peripheral1,829
- pneumonia1,716
- fatigue1,418
- drug ineffective1,169
- anaemia1,026
- asthenia1,024
- constipation1,001
- dyspnoea995
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4,416 |
| 2005 | 4,279 |
| 2006 | 809 |
| 2007 | 769 |
| 2008 | 2,021 |
| 2009 | 983 |
| 2010 | 900 |
| 2011 | 951 |
| 2012 | 956 |
| 2013 | 1,128 |
| 2014 | 1,621 |
| 2015 | 2,888 |
| 2016 | 1,716 |
| 2017 | 1,464 |
| 2018 | 1,456 |
| 2019 | 1,520 |
| 2020 | 1,487 |
| 2021 | 1,447 |
| 2022 | 1,635 |
| 2023 | 1,454 |
| 2024 | 1,182 |
| 2025 | 1,009 |
| 2026 | 600 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Thalomid (Thalidomide)
2024 spending
$19.8M
Beneficiaries
473
2,683 claims
Per beneficiary
$41,762
$225.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $33,138,478 |
| 2021 | $28,865,933 |
| 2022 | $24,535,859 |
| 2023 | $19,395,778 |
| 2024 | $19,753,380 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 'Experimental pregnancy' revisited.
Lyerly AD · Theor Med Bioeth 2022 · Randomized Controlled Trial
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Moreau P, Hulin C, Perrot A, et al. · Lancet Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia.
Chen H, Wu S, Tang M, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Multicenter Study
- Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.
Corre J, Vincent L, Moreau P, et al. · Blood 2025 · Clinical Trial, Phase III, Multicenter Study
- Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.
Yang G, Geng C, Jian Y, et al. · Adv Ther 2022 · Meta-Analysis, Systematic Review
- Thalidomide-induced neuropathy.
Chaudhry V, Cornblath DR, Corse A, et al. · Neurology 2002 · Case Reports, Clinical Trial
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.